Wells Fargo's economist forecasts GLP-1 weight-loss drugs like Ozempic and Mounjaro will reach about 90 million prescriptions, rivaling statins. This trend is driving demand for high-protein, low-volume foods suited for appetite-suppressed patients, benefiting companies like BellRing Brands, Eli Lilly, Novo Nordisk, Tyson Foods, and Hormel. Eli Lilly and Novo Nordisk lead drug production, while food companies adapt to shifting protein preferences. This emerging market quietly reshapes both pharmaceutical and food industries, offering new investment opportunities beyond the AI hype.
PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle during GLP-1 therapy. The report highlights growing industry interest, strategic acquisitions by ...
PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle mass alongside GLP-1 therapies. This emerging category is gaining industry attention due to its p...
The 4-Factor Dividend Growth Strategy, inspired by the Schwab US Dividend Equity ETF (SCHD), targets high-quality dividend stocks using four specific metrics. Since its inception, it has delivered an average 12-month return of 16.94%, outperforming S...
Weight Watchers has partnered with Eli Lilly's digital platform LillyDirect to offer its Med+ program, combining GLP-1 medication access with clinical and behavioral support. This integration aims to provide patients nationwide with a comprehensive w...
Chai Discovery, an AI drug discovery startup, has secured major partnerships with pharmaceutical giants Pfizer and Eli Lilly to develop new antibody-based therapies using its advanced AI models. Valued at $1.3 billion, Chai recently launched its impr...
